Protara Therapeutics Inc. (TARA)
TARA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TARA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001359931 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials
No annual revenue filed since the period ending 2014-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $25.1M cash; operating cash flow -$18.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,570,351 (2026-11-03); 38,587,260 a year earlier; 11,364,903 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-05-28 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, New York, New York, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$21.7M | -$18.4M | $25.1M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$21.7M | -$15.4M | $17.1M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2026 2026-03-31 | Not filed | -$17.8M | -$21.3M | $14.7M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2025 2025-12-31 | Not filed | -$17.3M | -$16.9M | $49.7M | No debt tags | Needs four quarters | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | Not filed | -$13.3M | -$12.5M | $12.6M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$15.0M | -$12.3M | $31.5M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2025 2025-03-31 | Not filed | -$11.9M | -$14.7M | $91.5M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2024 2024-12-31 | Not filed | -$12.8M | -$9.3M | $162.8M | No debt tags | Needs four quarters | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-05-28 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-10 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-06 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-06 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 812 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.0% |
| 1 month | -3.4% |
| 3 months | -35.8% |
| Year to date | -52.5% |
| 1 year | -52.0% |
| From 52-week high | -66.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HUMA | Humacyte Inc. | $0.5403 | -3.24% | $150.1M |
| STRO | Sutro Biopharma Inc. | $9.32 | -5.09% | $154.7M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier